Abstract: An object of the present invention is to provide a method of producing an intestinal epithelial cell, which has a large number of cells per area and a high accuracy of kinetic prediction for a CYP3A4 substrate drug such as midazolam, by inducing the differentiation of a pluripotent stem cell, as well as the intestinal epithelial cell, a cell sheet, an evaluation method for a test substance, a screening kit for a test substance, and a cell preparation.

Abstract: An object of the present invention is to provide a transportation instrument and a transportation method that enable transportation by using a cell culture container as it is. Further, an object of the present invention is to provide a transportation instrument and a transportation method that enable supply of oxygen required for respiration of cells. Further, an object of the present invention is to provide a transportation instrument and a transportation method that enable suppression of migration of a culture medium into and out of cells caused by the influence of an increase in internal pressure with respect to the temperature during transportation.

Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a method for producing an intestinal epithelial cell in which the barrier function is maintained while the differentiation of a pluripotent stem cell into a liver cell is suppressed and an intestinal epithelial cell in which the barrier function is maintained while the differentiation into a liver cell is suppressed. According to the present invention, provided is the method for producing an intestinal epithelial cell, including a step 1 of differentiating a pluripotent stem cell into an intestinal stem cell and a step 2 of differentiating the intestinal stem cell obtained in the step 1 into an intestinal epithelial cell in a presence of one or more selected from the group consisting of a MEK1 inhibitor, a DNA methylation inhibitor, and a TGF? receptor inhibitor, and EGF, in which during the step 2, a cell under differentiation is replated one or more times at the predetermined timing which is defined in the present specification.

Abstract: An object of the present invention is to provide a new means capable of easily and efficiently preparing cells showing a function more similar to the function of intestinal epithelial cells of a living body. According to the present invention, pluripotent stem cells are induced to differentiate into intestinal stem cell-like cells by a method for inducing differentiation of pluripotent stem cells into intestinal epithelial cells, the method including a step (1) of differentiating pluripotent stem, cells into intestinal stem cell-like cells and a step (2) of differentiating the intestinal stem cell-like cells obtained in the step (1) into intestinal epithelial cell-like cells by using an MEK1 inhibitor, a DNA methylation inhibitor, a TGF? receptor inhibitor, EGF, and a cAMP activator in combination.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: The present disclosure provides a blood vessel model including: a pair of channel members, mutually opposing each other, each of which includes an opposing face in which a respective microchannel is formed; and a porous membrane that includes plural through-holes penetrating in a thickness direction, that is disposed between the opposing faces of the pair of channel members, and that partitions between the microchannels, wherein the porous membrane is provided with a vascular endothelial cell layer so as to cover one face facing one of the microchannels, an average opening diameter of the through-holes is from 1 ?m to 20 ?m, and an opening coverage ratio of the through-holes is from 30% to 70%.

Abstract: A living tissue model device includes: a first liquid compartment storing a liquid composition; a second liquid compartment storing a liquid composition; and a cell layered body disposed between the first liquid compartment and the second liquid compartment, as a partition between both compartments. A vascular wall model includes: a porous membrane having a honeycomb structure; a vascular endothelial cell layer disposed on one face of the porous membrane; and a smooth muscle cell layer, or a mesenchymal stem cell layer, disposed on another face of the porous membrane. A vascular wall model device includes: a first liquid compartment storing a liquid composition; a second liquid compartment storing a liquid composition; and a vascular wall model disposed between the first liquid compartment and the second liquid compartment, as a partition between both compartments. Applications of these models or model devices are also provided.

Abstract: Provided is a method for producing a cell laminate including cell layers on both surfaces of a porous membrane, using a vessel having a bottom portion and a side wall portion standing from a periphery of the bottom portion, the porous membrane, and a holding member configured to hold the porous membrane such that the porous membrane faces an inner bottom surface of the vessel and is held at a position that does not contact the inner bottom surface, the method including culturing first cells in a liquid medium that contacts the inner bottom surface of the vessel and a surface of the porous membrane, in a state in which the porous membrane is held, by the holding member, at a position that does not contact the inner bottom surface of the vessel so as to face the inner bottom surface, and in which the bottom portion of the vessel is positioned at the upper side while the porous membrane is positioned at the lower side in a direction of gravity; and culturing the first cells at a lower surface of the porous membr

Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.

Abstract: The present disclosure provides a blood vessel model including: a pair of channel members, mutually opposing each other, each of which includes an opposing face in which a respective microchannel is formed; and a porous membrane that includes plural through-holes penetrating in a thickness direction, that is disposed between the opposing faces of the pair of channel members, and that partitions between the microchannels, wherein the porous membrane is provided with a vascular endothelial cell layer so as to cover one face facing one of the microchannels, an average opening diameter of the through-holes is from 1 ?m to 20 ?m, and an opening coverage ratio of the through-holes is from 30% to 70%.

Abstract: A living tissue model device includes: a first liquid compartment storing a liquid composition; a second liquid compartment storing a liquid composition; and a cell layered body disposed between the first liquid compartment and the second liquid compartment, as a partition between both compartments. A vascular wall model includes: a porous membrane having a honeycomb structure; a vascular endothelial cell layer disposed on one face of the porous membrane; and a smooth muscle cell layer, or a mesenchymal stem cell layer, disposed on another face of the porous membrane. A vascular wall model device includes: a first liquid compartment storing a liquid composition; a second liquid compartment storing a liquid composition; and a vascular wall model disposed between the first liquid compartment and the second liquid compartment, as a partition between both compartments. Applications of these models or model devices are also provided.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a non-human model animal rich in stromal tissue, a cell structure useful for producing the above-described non-human model animal, a method for evaluating a test substance in which the above-described non-human model animal is used, and a method for producing the above-described non-human model animal. According to the present invention, a cell structure is provided which contains a biocompatible macromolecular block and at least a cancer cell and a mesenchymal cell, and in which a plurality of the above-described biocompatible macromolecular blocks are arranged in gaps between a plurality of the above-described cells.